Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bamet-UD2
- Development stage
- Preclinical
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Not Specified In Available Data; Likely Intravenous Based On Class Analogs.
01
Overview
Bamet-UD2 is a novel experimental small molecule that combines a bile acid (ursodeoxycholic acid, UDCA) with a platinum-based chemotherapeutic agent (cisplatin). It is classified as a bile acid-platinum derivative. The drug was designed to enhance the liver-targeting properties of platinum compounds and reduce systemic toxicity. Preclinical studies have shown that Bamet-UD2 exhibits strong antitumor activity, particularly against liver tumors such as hepatoblastoma and hepatocellular carcinoma, with marked hepatobiliary organotropism—meaning it preferentially accumulates in the liver. Compared to conventional cisplatin, Bamet-UD2 demonstrates reduced nephrotoxicity, neurotoxicity, and bone marrow toxicity while maintaining or enhancing cytostatic effects on tumor cells[1][2][4][5][8]. Its mechanism of action involves DNA crosslinking via its platinum moiety (as with other platinum drugs), leading to inhibition of DNA replication and cell death in rapidly dividing tumor cells.
- Other names
- cis-diammine-bis-ursodeoxycholic platinum(II)cisplatin-ursodeoxycholate derivative
02
Targets
DNA
Beyond the preview
Go deeper on Bamet-UD2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bamet-UD2.